Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014, Article ID 818251, 11 pages
http://dx.doi.org/10.1155/2014/818251
Research Article

Activation of Adenosine A3 Receptor Alleviates TNF-α-Induced Inflammation through Inhibition of the NF-κB Signaling Pathway in Human Colonic Epithelial Cells

Department of Gastroenterology, The Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China

Received 8 February 2014; Accepted 14 March 2014; Published 22 April 2014

Academic Editor: Vinod K. Mishra

Copyright © 2014 Tianhua Ren et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. H. Ye and V. M. Rajendran, “Adenosine: an immune modulator of inflammatory bowel diseases,” World Journal of Gastroenterology, vol. 15, no. 36, pp. 4491–4498, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Haskó, J. Linden, B. Cronstein, and P. Pacher, “Adenosine receptors: therapeutic aspects for inflammatory and immune diseases,” Nature Reviews Drug Discovery, vol. 7, no. 9, pp. 759–770, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. B. B. Fredholm, G. Arslan, L. Halldner, B. Kull, G. Schulte, and W. Wasserman, “Structure and function of adenosine receptors and their genes,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 362, no. 4-5, pp. 364–374, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Gessi, S. Merighi, K. Varani, E. Leung, S. Mac Lennan, and P. A. Borea, “The A3 adenosine receptor: an enigmatic player in cell biology,” Pharmacology & Therapeutics, vol. 117, no. 1, pp. 123–140, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Ochaion, S. Bar-Yehuda, S. Cohen et al., “The anti-inflammatory target A3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease,” Cellular Immunology, vol. 258, no. 2, pp. 115–122, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Ochaion, S. Bar-Yehuda, S. Cohen et al., “The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-κB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats,” Biochemical Pharmacology, vol. 76, no. 4, pp. 482–494, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Y. Lee, B. S. Jhun, Y. T. Oh et al., “Activation of adenosine A3 receptor suppresses lipopolysaccharide-induced TNF-α production through inhibition of PI 3-kinase/Akt and NF-κB activation in murine BV2 microglial cells,” Neuroscience Letters, vol. 396, no. 1, pp. 1–6, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. H. T. Lee, M. Kim, D. J. Jin, G. Gallos, J.-F. Chen, and C. W. Emala, “A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 291, no. 4, pp. R959–R969, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. A. L. Maldonado-Contreras and B. A. McCormick, “Intestinal epithelial cells and their role in innate mucosal immunity,” Cell and Tissue Research, vol. 343, no. 1, pp. 5–12, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. J. R. Turner, “Intestinal mucosal barrier function in health and disease,” Nature Reviews Immunology, vol. 9, no. 11, pp. 799–809, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. M. G. Laukoetter, P. Nava, and A. Nusrat, “Role of the intestinal barrier in inflammatory bowel disease,” World Journal of Gastroenterology, vol. 14, no. 3, pp. 401–407, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. I. Atreya, R. Atreya, and M. F. Neurath, “NF-κB in inflammatory bowel disease,” Journal of Internal Medicine, vol. 263, no. 6, pp. 591–596, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. E. Spehlmann and L. Eckmann, “Nuclear factor-kappa B in intestinal protection and destruction,” Current Opinion in Gastroenterology, vol. 25, no. 2, pp. 92–99, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. S. Hayden and S. Ghosh, “Shared principles in NF-κB signaling,” Cell, vol. 132, no. 3, pp. 344–362, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Singh, R. Chaturvedi, D. P. Barry et al., “The apolipoprotein E-mimetic peptide COG112 inhibits NF-κB signaling, proinflammatory cytokine expression, and disease activity in murine models of colitis,” The Journal of Biological Chemistry, vol. 286, no. 5, pp. 3839–3850, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. H. B. Jijon, J. Walker, F. Hoentjen et al., “Adenosine is a negative regulator of NF-κB and MAPK signaling in human intestinal epithelial cells,” Cellular Immunology, vol. 237, no. 2, pp. 86–95, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Forte, R. Sorrentino, A. Montinaro, A. Pinto, and S. Morello, “Cl-IB-MECA enhances TNF-α release in peritoneal macrophages stimulated with LPS,” Cytokine, vol. 54, no. 2, pp. 161–166, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Ren, I. Grants, M. Alhaj et al., “Impact of disrupting adenosine A3 receptors (A3-/-AR) on colonic motility or progression of colitis in the mouse,” Inflammatory Bowel Diseases, vol. 17, no. 8, pp. 1698–1713, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. H.-S. Lee, H.-J. Chung, H. W. Lee, L. S. Jeong, and S. K. Lee, “Suppression of inflammation response by a novel A3 adenosine receptor agonist thio-Cl-IB-MECA through inhibition of Akt and NF-κB signaling,” Immunobiology, vol. 216, no. 9, pp. 997–1003, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Mabley, F. Soriano, P. Pacher et al., “The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis,” European Journal of Pharmacology, vol. 466, no. 3, pp. 323–329, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Guzman, J. G. Yu, Z. Suntres et al., “ADOA3R as a therapeutic target in experimental colitis: proof by validated high-density oligonucleotide microarray analysis,” Inflammatory Bowel Diseases, vol. 12, no. 8, pp. 766–789, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Antonioli, M. Fornai, R. Colucci et al., “The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors,” Journal of Pharmacology and Experimental Therapeutics, vol. 335, no. 2, pp. 434–442, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Pasparakis, “IKK/NF-κB signaling in intestinal epithelial cells controls immune homeostasis in the gut,” Mucosal Immunology, vol. 1, supplement 1, pp. S54–S57, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. Z. Li, D. K. Zhang, W. Q. Yi, Q. Ouyang, Y. Q. Chen, and H. T. Gan, “NF-kappaB p65 antisense oligonucleotides may serve as a novel molecular approach for the treatment of patients with ulcerative colitis,” Archives of Medical Research, vol. 39, no. 8, pp. 729–734, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Uwe, “Anti-inflammatory interventions of NF-κB signaling: potential applications and risks,” Biochemical Pharmacology, vol. 75, no. 8, pp. 1567–1579, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Elewaut, J. A. DiDonato, J. M. Kim, F. Truong, L. Eckmann, and M. F. Kagnoff, “NF-κB is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria,” Journal of Immunology, vol. 163, no. 3, pp. 1457–1466, 1999. View at Google Scholar · View at Scopus
  27. E. A. Van Schaick, K. A. Jacobson, H. O. Kim, A. P. Ijzerman, and M. Danhof, “Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats,” European Journal of Pharmacology, vol. 308, no. 3, pp. 311–314, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Yuan, G. Y. Bai, W. H. Park, S. Z. Kim, and S. H. Kim, “Stimulation of ANP secretion by 2-Cl-IB-MECA through A3 receptor and CaMKII,” Peptides, vol. 29, no. 12, pp. 2216–2224, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Sakowicz-Burkiewicz, A. Kitowska, M. Grden, I. Maciejewska, A. Szutowicz, and T. Pawelczyk, “Differential effect of adenosine receptors on growth of human colon cancer HCT 116 and HT-29 cell lines,” Archives of Biochemistry and Biophysics, vol. 533, no. 1-2, pp. 47–54, 2013. View at Google Scholar
  30. S. Gessi, S. Merighi, K. Varani et al., “Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A3 adenosine subtype,” Journal of Cellular Physiology, vol. 211, no. 3, pp. 826–836, 2007. View at Publisher · View at Google Scholar · View at Scopus